Medicine and Dentistry
Immune Checkpoint Blockade
79%
Neoplasm
74%
Malignant Neoplasm
59%
Mesothelioma
49%
Immunity
42%
Antineoplastic Activity
39%
Cyclophosphamide
39%
Tretinoin
39%
Toll Like Receptor Agonist
39%
Tumor Immunity
39%
Local Therapy
39%
Tumor Infiltrating Lymphocyte
39%
Lymphocyte
39%
Antimetabolite
39%
Resiquimod
33%
Polyinosinic Polycytidylic Acid
33%
Muscle Development
31%
Cytotoxic T-Cell
31%
Combination Therapy
22%
Tumor Microenvironment
19%
Cancer Model
19%
Cancer
19%
In Vitro
15%
Proteus Syndrome
15%
Tumor Model
12%
CTLA-4
11%
Chemotherapy
9%
Gene Expression
9%
T-Helper Cell
9%
Immunomodulatory Drug
9%
Side Effect
9%
Interferon
9%
Cell Line
9%
Transcriptomics
7%
Cell Invasion
7%
Pleura Mesothelioma
7%
Cell Growth
7%
Pleura Tumor
7%
Visceral Pleura
7%
Peritoneum
7%
Gene Expression Profiling
7%
Cell Migration
7%
Lymph Node
6%
Toll Like Receptor 3
6%
Debulking Surgery
6%
Monotherapy
6%
Drive
6%
Tumor Progression
6%
Low Drug Dose
6%
Toll Like Receptor 7
6%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Mesothelioma
66%
Neoplasm
63%
Pleura Mesothelioma
47%
Retinoic Acid
39%
Cyclophosphamide
39%
Peroxisome Proliferator Activated Receptor
39%
Geldanamycin
39%
Toll Like Receptor Agonist
39%
Chemotherapy
39%
Resiquimod
24%
Polyinosinic Polycytidylic Acid
24%
Murine
19%
CD8 Antigen
19%
Cancer Model
19%
Tumor Microenvironment
19%
Combination Therapy
14%
Pleura Tumor
13%
Side Effect
9%
Retinol Derivative
9%
Multiple Cancer
9%
Interferon
9%
Antiproliferative Activity
5%
Peroxisome Proliferator Activated Receptor Antagonist
5%
Cell Nucleus Receptor
5%
Dyspnea
5%
Immunology and Microbiology
Cyclophosphamide
79%
Immunity
55%
T-Helper Cell
49%
Interferon Type I
49%
Tumor Necrosis Factor Alpha
39%
Tumor-Infiltrating Lymphocytes
39%
Lymphocyte
39%
Metabolite
39%
Immune Checkpoint Blockade
39%
Gene Expression
36%
Cytotoxic T-Cell
31%
Murine
25%
RNA Sequence
13%
Immunotherapy
13%
Polyinosinic:polycytidylic Acid
13%
CTLA-4
11%
Tumor-Associated Macrophage
11%
Cell Line
9%
Immunomodulatory Drug
9%
Mouse Model
5%
Tumor Antigen
5%
Programmed Death-Ligand 1
5%
CD8
5%
Cell Death
5%
CD4
5%